Provided by Tiger Trade Technology Pte. Ltd.

Arrowhead Pharmaceuticals

65.79
-4.8800-6.91%
Post-market: 66.500.7100+1.08%19:30 EDT
Volume:5.11M
Turnover:342.43M
Market Cap:9.27B
PE:-28.81
High:71.93
Open:70.41
Low:64.50
Close:70.67
52wk High:95.49
52wk Low:28.48
Shares:140.86M
Float Shares:122.00M
Volume Ratio:2.18
T/O Rate:4.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2838
EPS(LYR):-0.0122
ROE:-55.21%
ROA:-8.10%
PB:19.91
PE(LYR):-5,395.72

Loading ...

Arrowhead posts Phase 1/2a data showing ARO-INHBE cuts liver fat 44% in obese adults

Reuters
·
May 27

Arrowhead presents clinical cardiometabolic data at EAS Congress

TIPRANKS
·
May 27

Arrowhead says study supports no plozasiran dose adjustment in moderate hepatic or moderate-to-severe renal impairment

Reuters
·
May 26

Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94TH European Atherosclerosis Society (Eas) Congress

THOMSON REUTERS
·
May 26

Arrowhead posts EAS case report on plozasiran use in FCS pregnancy

Reuters
·
May 26

How REDEMPLO Launch Momentum And SHASTA Phase 3 Milestones At Arrowhead Pharmaceuticals (ARWR) Has Changed Its Investment Story

Simply Wall St.
·
May 25

Arrowhead’s ARO-C3 Kidney Trial Reaches Completion, Setting Up the Next Catalyst for ARWR Investors

TIPRANKS
·
May 23

Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR), Black Diamond Therapeutics (BDTX) and Iovance Biotherapeutics (IOVA)

TIPRANKS
·
May 22

Arrowhead Pharmaceuticals (ARWR) Is Up 5.5% After Licensing ARO-PNPLA3 To Madrigal And Filing US$1B Shelf Registration - Has The Bull Case Changed?

Simply Wall St.
·
May 18

Arrowhead Pharmaceuticals Is Maintained at Market Perform by Bernstein

Dow Jones
·
May 14

Arrowhead Pharmaceuticals : Bernstein Raises Target Price to $46 From $35

THOMSON REUTERS
·
May 13

Arrowhead price target raised to $46 from $35 at Bernstein

TIPRANKS
·
May 13

Arrowhead Pharmaceuticals’ Earnings Call: Launch, Losses, Bets

TIPRANKS
·
May 09

Arrowhead Pharmaceuticals Is Maintained at Outperform by RBC Capital

Dow Jones
·
May 09

RBC Capital Adjusts Arrowhead Pharmaceuticals Price Target to $87 From $80, Maintains Outperform Speculative Risk Rating

MT Newswires Live
·
May 09

Stock Track | Arrowhead Pharmaceuticals Plummets 6.34% Intraday as Q2 Revenue Falls Short of Estimates

Stock Track
·
May 09

Arrowhead price target raised to $90 from $80 at Chardan

TIPRANKS
·
May 08

U.S. RESEARCH ROUNDUP-Applied Materials, McDonald's, McKesson

Reuters
·
May 08

Arrowhead Pharmaceuticals : Chardan Capital Markets Raises Target Price to $90 From $80

THOMSON REUTERS
·
May 08

Arrowhead reports Q2 EPS (93c), consensus ($1.11)

TIPRANKS
·
May 08